Proposal for the Classification of Relapsed and Refractory Acute Myeloid Leukemias as the Basis for an Age-Adjusted Randomized Comparison of Sequentially Applied High-Dose Versus Intermediate-Dose Cytosine Arabinoside in Combination with Mitoxantrone (S-HAM)

  • W. Hiddemann
  • H. C. Aul
  • G. Maschmeyer
  • D. Urbanitz
  • B. Lathan
  • A. Reichle
  • H. Köppler
  • R. Donhuijsen-Ant
  • W. D. Ludwig
  • T. Grüneisen
  • P. Bettelheim
  • W. Schroyens
  • L. Balleisen
  • H. Bartels
  • C. Sauerland
  • A. Heinecke
  • T. Büchner
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)

Abstract

In spite of the substantial improvement of first-line treatment in adult patients with acute myeloid leukemia (AML) and a grad-ual increase in long-term remissions, the majority of patients still relapse with their disease and ultimately die due to drug-resistant leukemia. More effective antileukemic therapy is therefore warranted and a variety of new drugs or new applications and dose ranges of established agents have been explored in clinical phase I and II studies. From these investigations cytosine arabinoside (Ara-C) obviously emerged as the most active single agent when administered at doses between 1.0 and 3.0 g/m2 over 4–6 days [1–7]. A more detailed analysis, however, reveals a substantial interstudy variation of response rates ranging from 11% to 70% even when considering only studies using the original Herzig regimen of 12 single doses of 3.0 g/m2 high-dose (HD) Ara-C [1–8].

Keywords

Leukemia Oncol Diarrhea Stratification Resis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Early AP, Preisler HD, Higby DJ, Brecher M, Browman G, McBride J A (1982) High-dose cytosine arabinoside. Clinical response to therapy in acute leukemia. Med Pediatr Oncol [Suppl 1]: 239Google Scholar
  2. 2.
    Willemze R, Zwaan FE, Colpin G, Keuning JJ (1982) High-dose cytosine arabinoside in the management of refractory acute leukaemia. Scand J Haematol 29: 141PubMedCrossRefGoogle Scholar
  3. 3.
    Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP (1983) High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62: 361PubMedGoogle Scholar
  4. 4.
    Cantin G, Brennan JK (1984) High-dose cytosine arabinoside for acute nonlymphocytic leukemia. Am J Hematol 16: 59PubMedCrossRefGoogle Scholar
  5. 5.
    Preisler HD, Epstein J, Barcos M, Priore R, Raza A, Browman GP, Vogler R, Winton E, Grunwald H, Rai K, Brennan J, Bennett J, Goldberg J, Gottlieb A, Chervenick P, Joyce R, Miller K, Larson R, D’Arrigo T, Doeblin T, Stein M, Bloom M, Steele R, Lee H (1984) Prediction of response of acute nonlymphocytic leukaemia to therapy with “high-dose” cytosine arabinoside. Br J Haematol 58: 19PubMedCrossRefGoogle Scholar
  6. 6.
    Takaku F, Urabe A, Mizoguchi H, Yamada O, Wakabayashi Y, Miura Y, Sakamoto S, Yoshida M, Miwa S, Asano S, Morisaki T, Nomura T, Toyama K, Aoki I, Murase T, Maekawa T, Miyawaki S, Murakami H, Yamada H, Ohno R, Kawashima K, Yokomaku S, Kinugasa K, Adachi Y, Mori M, Ise T, Mutoh Y, Yamaguchi H (1985) High-dose cytosine arabinoside in the treatment of resistant acute leukemia. Semin Oncol 12 [Suppl 3]: 144PubMedGoogle Scholar
  7. 7.
    Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ (1986) Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 81: 387PubMedCrossRefGoogle Scholar
  8. 8.
    Vogler WR, Preisler HD, Winton EF, Gottlieb AJ, Goldberg J, Brennan J, Grunwald H, Rai K, Browman G, Miller KB, Chervenick P, Azarnia N (1986) Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a leukemia intergroup study. Cancer Treat Rep 70: 455PubMedGoogle Scholar
  9. 9.
    Hiddemann W, Martin WR, Biichner T (1987) Definition of refractoriness to conventional therapy in advanced acute myeloid leukemia: an essential prerequisite for clinical phase I/II studies. Proc Am Assoc Cancer Res Am Soc Clin Oncol 6: 156Google Scholar
  10. 10.
    Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol (in press)Google Scholar
  11. 11.
    Biichner T, Urbanitz D, Hiddemann W, Riihl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, Nowrousian MR, Konig HJ, Walter M, Wendt FC, Sodomann H, Hossfeld DK, von Paleske A, Loffler H, Gassmann W, Hellriegel K-P, Fulle HH, Lunscken CH, Emmerich B, Pralle H, Pees HW, Pfreundschuh M, Bartels H, Koeppen K-M, Schwerdtfeger R, Donhuijsen-Ant R, Mainzer K, Bonfert B, Koppler H, Zurborn K-H, Ranft K, Thiel E, Heinecke A (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multi-center studies of the German AML Cooperative Group. J Clin Oncol 3: 1583Google Scholar
  12. 12.
    Buchner T, Hiddemann W, Koch P, Pielken H, Urbanitz D, Kreutzmann H, Maschmeyer G, Wendt F, Kuse R, Thiel E, Ludwig WD, Seibt H, Gassmann W, Loffler H, Aul C, Heyll A, Schneider W, Mertelsmann R, Anders CH, Nowrousian MR, Straif K, Hossfeld D, von Paleske A, Ho A, Fulle HH, Hellriegel K-P, Konig HJ, Emmerich B, Lengfelder E, Siegert W, Bartels H, Schwammborn J, Donhuijsen-Ant R, Vaupel HA, Konig E, Planker M, Middelhoff G, Mainzer K, Zurborn K-H, Koppler H, Nowicki L, Augener W, Karow J, Schroeder M, Eimermacher H, Sauerland MC, Heinecke A for the AML Cooperative Group. The role of maintenance chemotherapy, immunotherapy, induction dose reduction in elderly patients and double induction in the treatment of adult acute myeloid leukemia. Four randomized studies of the AML Cooperative Group. Blut (in press)Google Scholar
  13. 13.
    Hiddemann W, Aul C, Maschmeyer G, Lathan B, Koppler H, Hoffmann R, Griineisen T, Donhuijsen-Ant R, Ludwig WD, Balleisen L, Urbanitz D, Bettelheim P, Reichle A, Bartels H, Buchner T Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary results. Onkologie (in press)Google Scholar
  14. 14.
    Rees JKH, Swirsky D, Gray RG, Hayhoe FGJ (1986) Principal results of the Medical Research Councils’ 8th acute myeloid leukaemia trial. Lancet ii: 1236Google Scholar
  15. 15.
    Keating MJ, Estey E, Kantarjian H, Walters R, Smith T, McCredie KB, Freireich EJ (1987) Comparison of results of salvage therapy in adult acute myelogenous leukemia. Acta Haematol 78 [Suppl 1]: 120PubMedCrossRefGoogle Scholar
  16. 16.
    Riva CM, Rustum YM, Preisler HD (1985) Pharmacokinetics and cellular determinants of response to l-β-arabinofuranosylcytosine (Ara-C). Semin Oncol 12 [Suppl 3]: 1PubMedGoogle Scholar
  17. 17.
    Plunkett W, Lilienmark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ (1987) Saturation of 1-β-arabinofura-nosylcytosine 5’-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. Cancer Res 47: 3005PubMedGoogle Scholar
  18. 18.
    Kessel D, Hall TC, Wodinsky I (1967) Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science 156: 1240PubMedCrossRefGoogle Scholar
  19. 19.
    Chu MY, Fischer GA (1968) The incorporation of 3H-cytosine arabinoside and its effects on murine leukemia cells. Biochem Pharmacol 17: 753PubMedCrossRefGoogle Scholar
  20. 20.
    Momparler RL, Chu MY, Fischer GA (1968) Studies on a new mechanism of resistance of L 5178 Y murine leukemia cells to cytosine arabinoside. Biochem Biophys Acta 161: 481PubMedGoogle Scholar
  21. 21.
    Stewart CD, Burke PJ (1971) Cytidine deaminase and development of resistance to arabinosyl cytosine. Nature 223: 109Google Scholar
  22. 22.
    Tattersall MHN, Ganeshaguru K, Hoffbrand AV (1974) Mechanisms of resistance of human acute leukemia cells to cytosine arabinoside. Br J Haematol 27: 39PubMedCrossRefGoogle Scholar
  23. 23.
    Abe I, Sato S, Honi K, Suzuki M, Sato H (1982) Role of dephosphorylation in accumulation of l-/?-D-arabinofuranosylcytosine 5’-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Cancer Res 42: 2846PubMedGoogle Scholar
  24. 24.
    Willemze R, Fibbe WE, Zwaan FE (1983) Experience with intermediate and high-dose cytosine arabinoside in refractory acute leukemia. Onkologie 6: 200PubMedCrossRefGoogle Scholar
  25. 25.
    Herzig RH, Hines JD, Herzig GP, Wolff SN, Cassileth PA, Lazarus HM, Adelstein DJ, Brown RA, Coccia PF, Strandjord S, Mazza JJ, Fay J, Phillips GL (1987) Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 5: 927PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • W. Hiddemann
    • 1
  • H. C. Aul
    • 2
  • G. Maschmeyer
    • 3
  • D. Urbanitz
    • 4
  • B. Lathan
    • 5
  • A. Reichle
    • 6
  • H. Köppler
    • 7
  • R. Donhuijsen-Ant
    • 8
  • W. D. Ludwig
    • 9
  • T. Grüneisen
    • 10
  • P. Bettelheim
    • 11
  • W. Schroyens
    • 12
  • L. Balleisen
    • 13
  • H. Bartels
    • 14
  • C. Sauerland
    • 15
  • A. Heinecke
    • 15
  • T. Büchner
    • 1
  1. 1.Departments of Internal MedicineUniversity of MünsterGermany
  2. 2.Departments of Internal MedicineUniversity of DüsseldorfGermany
  3. 3.Departments of Internal MedicineUniversity of Ev. Krankenhaus Essen-WerdenGermany
  4. 4.Departments of Internal MedicineUniversity of St. Bernward Krankenhaus HildesheimGermany
  5. 5.Departments of Internal MedicineUniversity of KölnGermany
  6. 6.Departments of Internal MedicineUniversity of München InnenstadtGermany
  7. 7.Departments of Internal MedicineUniversity of MarburgGermany
  8. 8.Departments of Internal MedicineUniversity of St.-Josefs-Hospital Duisburg-HambornGermany
  9. 9.Departments of Internal MedicineUniversity of FU BerlinGermany
  10. 10.Departments of Internal MedicineUniversity of Krankenhaus Berlin-NeuköllnGermany
  11. 11.Departments of Internal MedicineUniversity of WienAustria
  12. 12.Departments of Internal MedicineUniversity of GiessenGermany
  13. 13.Departments of Internal MedicineUniversity of Ev. Krankenhaus HammGermany
  14. 14.Departments of Internal MedicineUniversity of Städt. Krankenhaus Süd LübeckGermany
  15. 15.Departments of Internal MedicineUniversity of Institut für Medizinische Dokumentation und Informatik Univ. MünsterGermany

Personalised recommendations